Novartis
NEWS
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
Novartis will quickly roll Mayzent out to U.S. physicians. The Swiss pharma giant plans to make the drug available within one week of the FDA approval.
Alcon will officially step out from under the Novartis umbrella on April 9 as it will trade on the NYSE and the SIX Swiss Exchange.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
Alcon said the acquisition of PowerVision demonstrates its commitment to bringing advanced technology intraocular lenses to cataract patients across the globe.
Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis
Alex Trebek, 78, host of TV game show “Jeopardy” announced yesterday that he had been diagnosed with stage 4 pancreatic cancer.
With its concerns over drug pricing and potential questions of “pay-to-play” for access to the White House, Congress did not miss the chance to question President Donald Trump’s former attorney about his relationship with Novartis.
JOBS
IN THE PRESS